ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.
A phase 1/2 trial of CAPOX, Sintilimab, Tislelizumab in oesophageal cancer, run by AskGene Pharma, Inc., active and no longer recruiting.
Overview
ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer. is a phase 1/2 interventional study registered as NCT05632939 by AskGene Pharma, Inc., with 62 participants enrolled, started 2023-02-21 and due to reach its primary completion in 2025-10-31. Interventions recorded: ASKB589 +CAPOX+Sintilimab/Tislelizumab. Conditions listed: Gastric Cancer, Gastroesophageal Cancer (GC). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialRATIONALE-306
Shares Tislelizumab, Oesophageal cancer.
- TrialRATIONALE-302
Shares Tislelizumab, Oesophageal cancer.
- TrialA Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Shares Tislelizumab, Oesophageal cancer.
- TrialSKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Shares Tislelizumab, Oesophageal cancer.
- TrialA Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States
Shares Tislelizumab, Oesophageal cancer.
- TrialHERIZON-GEA-01
Shares Tislelizumab, Oesophageal cancer.
- TrialCheckMate 649
Shares CAPOX (capecitabine, oxaliplatin), Oesophageal cancer.
- CollectionCSCO guidelines (China)
Shares Tislelizumab, Oesophageal cancer.